MARKET

SION

SION

Sionna Therapeutics
NASDAQ
3.330
-0.100
-2.92%
After Hours: 3.300 -0.03 -0.90% 18:44 11/13 EST
OPEN
3.430
PREV CLOSE
3.430
HIGH
3.575
LOW
3.250
VOLUME
470.08K
TURNOVER
--
52 WEEK HIGH
54.97
52 WEEK LOW
3.190
MARKET CAP
150.63M
P/E (TTM)
-1.3690
1D
5D
1M
3M
1Y
5Y
1D
Sionna Therapeutics, Inc. (SION) Receives a Rating Update from a Top Analyst
TipRanks · 9h ago
RBC Capital Keeps Their Hold Rating on Sionna Therapeutics, Inc. (SION)
TipRanks · 22h ago
BTIG Remains a Hold on Sionna Therapeutics, Inc. (SION)
TipRanks · 2d ago
Sionna Posts Wider Loss In Q3 With 46% Workforce Cut; Phase 2 Cystic Fibrosis Trial Set For Q1 2027
NASDAQ · 2d ago
Sionna Therapeutics reports Q3 EPS (72c), consensus (68c)
TipRanks · 3d ago
Sionna Therapeutics GAAP EPS of -$0.72 misses by $0.09
Seeking Alpha · 3d ago
*Sionna Therapeutics 3Q Loss $32.4M >SION
Dow Jones · 3d ago
Press Release: Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Dow Jones · 3d ago
More
About SION
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

Webull offers Sionna Therapeutics, Inc. stock information, including NASDAQ: SION real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SION stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SION stock methods without spending real money on the virtual paper trading platform.